Moreover, Secukinumab was ineffective and resulted in higher rates of adverse events, mainly infections, compared with placebo in patients with Crohn's disease [156], and the study in MS terminated early based upon development of another anti-IL-17 monoclonal antibody with better potential for treating MS patients, Ixekizumab (NCT02387801 Clinicaltrial.gov). The gene discussed is IL17A; the disease is Crohn disease.